SCNI — Scinai Immunotherapeutics Ltd.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1611747 ·
Last close
$0.37
Market Cap
$252.4K
52W High
$13.00
52W Low
$0.36
ADV30
2,320,735
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,856,000 | -601,000 | -1,950,000 | -1,967,000 | 15,698,000 | 1,712,000 | 4,984,000 |
| Jun 2026 | 460,000 | -1,252,000 | -2,146,000 | -2,003,000 | 17,175,000 | 2,654,000 | 5,443,000 |
| Mar 2026 | 489,000 | -1,118,000 | -2,467,000 | 3,577,000 | 17,588,000 | 2,963,000 | 5,827,000 |
| Dec 2025 | — | — | — | — | 11,626,000 | 1,661,000 | 3,523,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,495,000
Investing CF
$2,624,000
Financing CF
$3,907,000
CapEx
$-127,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.38
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-124,272,000
Inventory
—
Receivables
$635,000
ST Investments
—
EBIT TTM
$-1,975,000
Pretax Income TTM
$-2,560,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,487,000
EBITDA
$-6,636,000
Free Cash Flow
$-3,657,250
Enterprise Value
$7,499,236
Total Cash
$2,654,000
Total Debt
$3,580,000
Shares Out
677,581
Trailing EPS
$28.07
Book Value
$10.71
ROE
-26.5%
ROA
-36.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,311,000 | -7,542,000 | -8,307,000 | 11,600,000 | 3,523,000 | 8,103,000 | -6,031,000 |
| Dec 2024 | 658,000 | -8,638,000 | 4,796,000 | 13,400,000 | 3,470,000 | 9,977,000 | -6,335,000 |
| Dec 2023 | 0 | -9,706,000 | -6,500,000 | 17,500,000 | 22,041,000 | -4,569,000 | -9,382,000 |
| Dec 2022 | 0 | -11,061,000 | -5,796,000 | 27,100,000 | 28,827,000 | -1,760,000 | -7,265,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$23,292,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CERO | CERO THERAPEUTICS HOLDINGS, INC. | $290.1K | $0.00 | — |
| CPMV | Mosaic ImmunoEngineering Inc. | $550.4K | $0.08 | — |
| GPLB | Green Planet Bio Engineering Co. Ltd. | $580.2K | $0.03 | — |
| SLXN | Silexion Therapeutics Corp | $1.07M | $1.65 | — |
| AGTX | Agentix Corp. | $1.35M | $0.03 | — |
News headlines (Yahoo Finance, 1h cache)
Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands
2026-11-05 13:00 · Yahoo
Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing
2026-10-20 12:35 · Yahoo
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement
2026-10-16 12:00 · Yahoo
Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement
2026-10-14 12:00 · Yahoo
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
2026-10-13 11:00 · Yahoo
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-09-21 11:00 · Yahoo
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
2026-09-08 13:15 · Yahoo
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
2026-08-24 11:00 · Yahoo
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
2026-08-10 10:34 · Yahoo
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
2026-06-10 11:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.